Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals
- Transaction reduces royalty and milestone obligations for LIVMARLI® and volixibat
- Cash flow positive transaction
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it has acquired Satiogen Pharmaceuticals, Inc., a San Diego-based company. Satiogen, now a wholly-owned Mirum subsidiary, was an existing licensing partner for LIVMARLI® (maralixibat) oral solution and volixibat. Through the transaction, Mirum obtained all Satiogen licensing payments and Satiogen-owned intellectual property relating to LIVMARLI and volixibat.
"The acquisition of Satiogen is a strategic step that consolidates the economics of our commercial and pipeline programs," said Chris Peetz, president and
